Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

NCT04144036 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Graft-versus-host Disease

Interventions

BIOLOGICAL: Neihulizumab, 3 mg/kg
DRUG: Neihulizumab, 6 mg/kg
DRUG: Neihulizumab, 9 mg/kg
DRUG: Neihulizumab

Sponsor

Sameem M. Abedin, MD